Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28139877 | 0.73 | MGLL (0.43) | MGLLGSK3AGSK3BFAAHALDH1A1 | |
| SCHEMBL9876672 | 0.68 | — | — | |
| SCHEMBL20320446 | 0.67 | — | — | |
| SCHEMBL21610792 | 0.65 | — | — | |
| SCHEMBL21610408 | 0.65 | — | — | |
| SCHEMBL21610759 | 0.62 | ALOX5 (0.32) | — | |
| SCHEMBL20320708 | 0.62 | CAPN1 (0.32) | MGLL | |
| SCHEMBL21610906 | 0.62 | — | — | |
| SCHEMBL20320505 | 0.62 | — | — | |
| SCHEMBL28231995 | 0.62 | ADRA2C (0.40) | MAPK1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377551-B1 | ANTIPROLIFERATIVE AGENTS | EPX RES LTD (GB) | 2011-09-14 | — | — | EP | disclosed |
| US-7750181-B2 | Antiproliferative agents | EPX RESEARCH LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-7049338-B2 | Antiproliferative agents | EPX RESEARCH LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| US-20050176779-A1 | Antiproliferative agents | EPX RESEARCH LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20050165066-A1 | Antiproliferative agents | EPX RESEARCH LIMITED (GB) | 2005-07-28 | — | — | US | disclosed |
| US-6881846-B2 | Antiproliferative agents | EPX RESEARCH LIMITED (GB) | 2005-04-19 | — | — | US | disclosed |
| US-20040106648-A1 | Antiproliferative agents | EPX RESEARCH LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1377551-A1 | ANTIPROLIFERATIVE AGENTS | EPX Research Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002072553-A1 | ANTIPROLIFERATIVE AGENTS | EPX RESEARCH LIMITED (GB) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165066-A1 | Antiproliferative agents | MKI67, PCNA, DUT | MGLL 3477/4885GSK3A 2638/4885GSK3B 3063/4885 |
| US-20040106648-A1 | Antiproliferative agents | MKI67, PCNA, DUT | MGLL 3477/4885GSK3A 2638/4885GSK3B 3063/4885 |
| US-20050176779-A1 | Antiproliferative agents | MKI67, PCNA, DUT | MGLL 3477/4885GSK3A 2638/4885GSK3B 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.